NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.03. The biotechnology company earned $0.24 million during the quarter, compared to analyst estimates of $7 million. View Adaptimmune Therapeutics' Earnings History.

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

7 equities research analysts have issued 1-year target prices for Adaptimmune Therapeutics' shares. Their forecasts range from $4.15 to $8.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $6.03 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Media stories about ADAP stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Adaptimmune Therapeutics.

Adaptimmune Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,530,000 shares, a decline of 35.2% from the December 15th total of 2,360,000 shares. Based on an average daily trading volume, of 412,800 shares, the days-to-cover ratio is presently 3.7 days. Currently, 1.7% of the shares of the company are short sold. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Regenxbio (RGNX), Editas Medicine (EDIT), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Orchard Therapeutics (ORTX), Alector (ALEC), Coherus Biosciences (CHRS), DBV TECHNOLOGIE/S (DBVT), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA) and AVITA MED LTD/S (RCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Second Sight Medical Products (EYES), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Chipotle Mexican Grill (CMG) and Micron Technology (MU).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $4.52.

Adaptimmune Therapeutics has a market capitalization of $473.20 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]